Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range433.10 - 4,200.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪21.30M
Enterprise Value8.79B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance-sheet FlexibilityVery low debt reduces refinancing and covenant risk and gives management flexibility to fund clinical programs or pursue partnerships without immediate solvency pressure. This structural conservatism lengthens runway versus highly levered peers and supports survival through multi-stage R&D cycles.
Specialized A3AR-focused Clinical PipelineA concentrated scientific focus on A3AR drugs creates institutional expertise and a clearer development pathway across inflammatory, liver and oncology indications. That specialization can produce durable competitive advantages in trial design, regulatory strategy and partner interest if clinical signals validate the approach.
Very High Gross Margins On Reported ActivityExtremely high gross margins imply low incremental cost to deliver drug candidates or license IP, a structural advantage when/if commercial revenues emerge. If fixed operating costs are controlled and trials succeed, this margin profile supports sustainable profitability at scale despite current development-stage losses.
Bears Say
Very Small And Shrinking Revenue BaseA declining, negligible top line undermines self-funding capacity and signals limited near-term commercial traction. Sustained revenue shrinkage forces reliance on external capital, constrains reinvestment in trials, and increases execution risk for pipeline advancement over the next several quarters.
Large, Worsening Operating And Net LossesEscalating operating and net losses erode equity value and heighten the need for dilutive financings or partner deals. A cost base that does not scale down with activity makes it harder to reach cash-flow breakeven, pressuring long-term viability absent clear clinical or commercial inflection points.
Consistent Negative Operating And Free Cash FlowPersistent cash burn, even if slightly improved in 2025, means the company cannot self-fund development and will likely need external financing. Recurring cash deficits create dilution risk, limit strategic optionality, and constrain the pace of clinical programs over the medium term.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 433.10 and its highest was 4200.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪21.30M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 108 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -18.278 earnings per share for the quarter, beating the consensus estimate of -20.309 by 2.031.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -18.278 in its last earnings report, beating expectations of -20.309. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.